{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GSK1265744+30+mg+oral", "query": { "intervention": "GSK1265744 30 mg oral" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 26, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GSK1265744+30+mg+oral&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-07T08:16:04.699Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02411435", "title": "Effect of Rifampin (RIF) on the Pharmacokinetics (PK) of Oral Cabotegravir (CAB) in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Infection, Human Immunodeficiency Virus" ], "interventions": [ { "name": "CAB", "type": "DRUG" }, { "name": "RIF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 15, "start_date": "2015-07", "completion_date": "2015-09", "has_results": false, "last_update_posted_date": "2016-01-06", "last_synced_at": "2026-10-07T08:16:04.699Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02411435" }, { "nct_id": "NCT04692077", "title": "Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Males", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Cabotegravir (CAB) tablet", "type": "DRUG" }, { "name": "CAB LA", "type": "DRUG" }, { "name": "Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": "17 Years", "sex": "MALE", "summary": "Up to 17 Years · Male only" }, "enrollment_count": 9, "start_date": "2020-02-19", "completion_date": "2023-07-07", "has_results": true, "last_update_posted_date": "2025-05-20", "last_synced_at": "2026-10-07T08:16:04.699Z", "location_count": 4, "location_summary": "Aurora, Colorado • Chicago, Illinois • Boston, Massachusetts + 1 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04692077" }, { "nct_id": "NCT02178800", "title": "Evaluating the Safety, Tolerability, and Pharmacokinetics of an Investigational, Injectable HIV Medicine (GSK1265744) in HIV-Uninfected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "GSK1265744 Tablets", "type": "DRUG" }, { "name": "Injectable GSK1265744", "type": "DRUG" }, { "name": "Placebo for GSK1265744 Tablets", "type": "DRUG" }, { "name": "Injectable Placebo for GSK1265744", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 199, "start_date": "2015-02", "completion_date": "2018-07-13", "has_results": true, "last_update_posted_date": "2021-10-18", "last_synced_at": "2026-10-07T08:16:04.699Z", "location_count": 4, "location_summary": "Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02178800" }, { "nct_id": "NCT02720094", "title": "Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Cabotegravir Oral Tablet", "type": "DRUG" }, { "name": "TDF/FTC tablets", "type": "DRUG" }, { "name": "Placebo for TDF/FTC tablets", "type": "DRUG" }, { "name": "Placebo for cabotegravir oral tablet", "type": "DRUG" }, { "name": "CAB LA", "type": "DRUG" }, { "name": "Placebo for CAB LA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4570, "start_date": "2016-12-19", "completion_date": "2025-03-31", "has_results": true, "last_update_posted_date": "2026-03-19", "last_synced_at": "2026-10-07T08:16:04.699Z", "location_count": 27, "location_summary": "Birmingham, Alabama • Los Angeles, California • Oakland, California + 20 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02720094" }, { "nct_id": "NCT02027454", "title": "Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Infection, Human Immunodeficiency Virus" ], "interventions": [ { "name": "GSK1265744", "type": "DRUG" }, { "name": "GSK1265744 matching placebo", "type": "DRUG" }, { "name": "Moxifloxacin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 42, "start_date": "2014-01", "completion_date": "2014-06", "has_results": false, "last_update_posted_date": "2014-06-16", "last_synced_at": "2026-10-07T08:16:04.699Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02027454" }, { "nct_id": "NCT03299049", "title": "Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Cabotegravir Tablets", "type": "DRUG" }, { "name": "Rilpivirine Tablets", "type": "DRUG" }, { "name": "Cabotegravir Injectable Suspension", "type": "DRUG" }, { "name": "Rilpivirine Injectable Suspension", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1049, "start_date": "2017-10-27", "completion_date": "2029-12-31", "has_results": true, "last_update_posted_date": "2025-08-22", "last_synced_at": "2026-10-07T08:16:04.699Z", "location_count": 43, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 33 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03299049" }, { "nct_id": "NCT04371380", "title": "Pharmacokinetic Study of Cabotegravir and Rilpivirine Long-acting Intramuscular Injections in Healthy Adult Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Cabotegravir Tablets", "type": "DRUG" }, { "name": "Rilpivirine Tablets", "type": "DRUG" }, { "name": "Cabotegravir extended release suspension for injection (long-acting)", "type": "DRUG" }, { "name": "Rilpivirine extended release suspension for injection (long-acting)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 15, "start_date": "2020-09-16", "completion_date": "2021-12-26", "has_results": true, "last_update_posted_date": "2024-04-22", "last_synced_at": "2026-10-07T08:16:04.699Z", "location_count": 1, "location_summary": "Glendale, California", "locations": [ { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04371380" }, { "nct_id": "NCT01848340", "title": "An Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1265744 Administered as a Single Oral Dose and a Study to Describe the Pharmacokinetics of a Supratherapeutic Dose of GSK1265744 in Healthy Adult Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV-associated Lipodystrophy Syndrome" ], "interventions": [ { "name": "GSK1265744B (sodium salt) containing 14C-GSK1265744B", "type": "DRUG" }, { "name": "150 mg GSK1265744B", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 16, "start_date": "2013-05", "completion_date": "2013-07", "has_results": false, "last_update_posted_date": "2013-11-04", "last_synced_at": "2026-10-07T08:16:04.699Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01848340" }, { "nct_id": "NCT02799264", "title": "A Study to Evaluate the Effect of High Fat Meal on Cabotegravir", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Infection, Human Immunodeficiency Virus" ], "interventions": [ { "name": "Cabotegravir 30 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 24, "start_date": "2016-06", "completion_date": "2016-08", "has_results": false, "last_update_posted_date": "2017-01-13", "last_synced_at": "2026-10-07T08:16:04.699Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02799264" }, { "nct_id": "NCT04542070", "title": "A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Cabotegravir Tablets", "type": "DRUG" }, { "name": "Cabotegravir Injectable Suspension (CAB LA)", "type": "DRUG" }, { "name": "Rilpivirine Tablets", "type": "DRUG" }, { "name": "Rilpivirine Injectable Suspension (RPV LA)", "type": "DRUG" }, { "name": "BIKTARVY Tablets (BIK)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 687, "start_date": "2020-11-09", "completion_date": "2023-04-17", "has_results": true, "last_update_posted_date": "2024-06-04", "last_synced_at": "2026-10-07T08:16:04.699Z", "location_count": 41, "location_summary": "Bakersfield, California • Beverly Hills, California • Los Angeles, California + 32 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04542070" } ] }